शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
CONCORDBIONSEConcord Biotech Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 11 Feb, 2026 · 19:27 IST

Concord Biotech Q3 FY26: revenue up 14% YoY, 9M PAT down 25%

Revenue declinedExceptional itemResults View source PDFExplain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹1243.80
prior close
₹1200.00
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%-0.8% vs market
Pharmaceuticals peers, median of 157sector-0.6%-0.9% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.4
10m
+3.3
15m
+3.4
30m
+4.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.5-0.7-0.8-0.6-0.9
Next day
-4.8-2.3-2.5-1.4-3.5
2d
-6.6-2.4-4.2-2.1-4.5
3d
-7.9-1.7-6.3-1.6-6.4
4d
-7.5-1.2-6.4-1.6-6.0
5d
-10.6-2.3-8.3-2.4-8.2
1w
-11.3-2.1-9.2-2.9-8.4
15d
-2.9-5.8+2.9-6.5+3.6
1m
-5.3-6.7+1.5-6.6+1.4
2m
-15.6-4.2-11.4-3.3-12.3
3m
-8.4+2.2-10.7+0.9-9.3
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q3 FY26 revenue rose 14% YoY to Rs 27,813 lakhs, but 9M FY26 revenue fell 5% to Rs 72,918 lakhs. Standalone Q3 PAT was Rs 6,778 lakhs (down 8.5% YoY), while 9M PAT dropped 25% to Rs 17,324 lakhs. Q3 EPS stood at Rs 6.48 versus Rs 7.08. An exceptional charge of Rs 327.54 lakhs was booked for new labour codes. Auditor BSR and Co. LLP issued an unmodified review opinion. Paritosh Trivedi appointed as new Company Secretary.

Likely market impact

9M profit down sharply despite Q3 revenue growth, pointing to margin pressure. One-time labour code charge recognized. Watch for sustainability of recovery.